GSK's experimental IL-5 inhibitor depemokimab has shown its potential in a pair of phase 3 trials in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The company said this morning ...

Regulators in the EU, China, and Japan have started reviews of GSK's depemokimab, aiming to become the first drug for severe asthma that can be given just twice a year. The EMA and counterparts in ...

In other recent news, GSK plc has reported several significant developments. The company announced that the US FDA has accepted its Biologics License Application for depemokimab, targeting asthma ...

In other recent news, GSK plc has reported several significant developments. The company announced that the US FDA has accepted its Biologics License Application for depemokimab, targeting asthma and ...

GSK has secured the first regulatory approval for Blenrep since the antibody-drug conjugate’s global market withdrawal in 2022. The U.K.’s Medicines and Healthcare products Regulatory Agency ...

GSK has been found guilty of bringing discredit on the pharma industry after a complainant flagged “a shocking error” in the prescribing information for the JAK inhibitor Omjjara. A person who ...

At its 52-week peak on 16 May 2024, the GSK share price hit 1,823.5p, but it’s been mostly downhill ever since. Last week, as stock markets crashed, GSK shares collapsed to 1,242.5p on Wednesday 9 ...